The poor prognosis of G3 MBs is related to the young age of metastases (~50% of patients vs. 55.55% in our cohort) at diagnosis, large cell/anaplastic (LCA) histology (25% of tumors in our cohort), and MYC amplification (33). The gene discussed is MYC; the disease is Mobius syndrome.